source
- Shionogi to acquire Texas-based IntraBio for $2 billion, adding marketed rare-disease drug AqneursaShionogi announced Monday it will buy IntraBio, a Texas biotech, for $2 billion in cash, making IntraBio a wholly owned subsidiary of its U.S. division. The deal gives Shionogi ownership of Aqneur…
- AI drives faster drug development and reshapes biopharma manufacturing facilitiesAI is speeding up the identification of drug candidates, turning years of laboratory work into months by analyzing large biological datasets and accelerating early‑stage development. This accelera…